COSCIENS Biopharma Inc. Selling, General and Administrative Expense
COSCIENS Biopharma Inc. (CSCIF) reported Selling, General and Administrative Expense of $10.06 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:SellingGeneralAndAdministrativeExpense · last filed 2026-03-25
- COSCIENS Biopharma Inc. selling general and administrative expense for the quarter ending 2025-12-31 was $2.40M, a 12.67% decline year-over-year.
- COSCIENS Biopharma Inc. selling general and administrative expense for the quarter ending 2025-09-30 was $2.10M, a 29.78% decline year-over-year.
- COSCIENS Biopharma Inc. selling general and administrative expense for the quarter ending 2025-06-30 was $2.64M, a 13.37% decline year-over-year.
- COSCIENS Biopharma Inc. selling general and administrative expense for the quarter ending 2025-03-31 was $2.93M, a 76.69% increase year-over-year.
| Period end | Selling General And Administrative Expense 3 month | Selling General And Administrative Expense 6 month | Selling General And Administrative Expense 9 month | Selling General And Administrative Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.40M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-25 | $4.50M derived: sum of 2 quarters · filed 2026-03-25 | $7.14M derived: sum of 3 quarters · filed 2026-03-25 | $10.06M 20-F · filed 2026-03-25 |
| 2025-09-30 | $2.10M 6-K · filed 2025-11-12 | $4.74M derived: sum of 2 quarters · filed 2025-11-12 | $7.66M 6-K · filed 2025-11-12 | $10.41M derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-06-30 | $2.64M 6-K · filed 2025-08-14 | $5.56M 6-K · filed 2025-08-14 | $8.31M derived: sum of 3 quarters · filed 2026-03-25 | $11.30M derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-03-31 | $2.93M 6-K · filed 2025-05-13 | $5.67M derived: sum of 2 quarters · filed 2026-03-25 | $8.66M derived: sum of 3 quarters · filed 2026-03-25 | $11.71M derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-12-31 | $2.75M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-25 | $5.74M derived: sum of 2 quarters · filed 2026-03-25 | $8.78M derived: sum of 3 quarters · filed 2026-03-25 | $10.45M 20-F · filed 2026-03-25 |
| 2024-09-30 | $2.99M 6-K · filed 2025-11-12 | $6.04M derived: sum of 2 quarters · filed 2025-11-12 | $7.70M 6-K · filed 2025-11-12 | $9.39M derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-06-30 | $3.04M 6-K · filed 2025-08-14 | $4.71M 6-K · filed 2025-08-14 | $6.39M derived: sum of 3 quarters · filed 2026-03-25 | $7.88M derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-03-31 | $1.66M 6-K · filed 2025-05-13 | $3.35M derived: sum of 2 quarters · filed 2026-03-25 | $4.83M derived: sum of 3 quarters · filed 2026-03-25 | $6.05M derived: sum of 4 quarters · filed 2026-03-25 |
| 2023-12-31 | $1.70M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-25 | $3.17M derived: sum of 2 quarters · filed 2026-03-25 | $4.39M derived: sum of 3 quarters · filed 2026-03-25 | $5.53M 20-F · filed 2026-03-25 |
| 2023-09-30 | $1.48M 6-K · filed 2024-11-12 | $2.70M derived: sum of 2 quarters · filed 2024-11-12 | $3.83M 6-K · filed 2024-11-12 | |
| 2023-06-30 | $1.22M 6-K · filed 2024-08-13 | $2.35M 6-K · filed 2024-08-13 | ||
| 2022-12-31 | $2.87M 20-F · filed 2025-04-09 |